← All organizations
Highest phase reached
Phase 3
Timeline
1990s
- Jul 1, 1996
Dynavax Technologies Corporation— Founded
2010s
- Nov 9, 2017
hepatitis b vaccine (recombinant)— NDA Secondary Org
Drugs by trial phase (23 distinct, 28 trials)
Phase 3 (2 own, 0 via acquisition)
Phase 2 (11 own, 0 via acquisition)
Phase 1 (10 own, 0 via acquisition)
Indications
Studied for
- Adenocarcinoma
- Carcinoma
- Carcinoma, Non-Small-Cell Lung
- Carcinoma, Squamous Cell
- Colorectal Neoplasms
- Head and Neck Neoplasms
- Hepatitis
- Hepatitis A
- Hepatitis B
- Hepatitis B, Chronic
- Hepatitis C
- Hepatitis C, Chronic
- Hepatitis, Chronic
- HIV Infections
- Kidney Diseases
- Kidney Failure, Chronic
- Lung Neoplasms
- Lymphoma
- Lymphoma, B-Cell
- Lymphoma, Non-Hodgkin
- Melanoma
- Pancreatic Neoplasms
- Renal Insufficiency, Chronic
- Rhinitis
- Rhinitis, Allergic
- Rhinitis, Allergic, Seasonal
- Squamous Cell Carcinoma of Head and Neck
Marketed drugs (1)
Recent trials (43)
- NCT07207408Lead sponsorPhase 2Sep 11, 2025
- NCT06569823Lead sponsorPhase 1/Phase 2Jun 17, 2024
- NCT06569823OfficialPhase 1/Phase 2Jun 17, 2024
- NCT05506969Lead sponsorPhase 2Aug 9, 2022
- NCT05506969Study chairPhase 2Aug 9, 2022
- NCT05245838Lead sponsorPhase 1Jan 10, 2022
- NCT05245838Study chairPhase 1Jan 10, 2022
- NCT04385524CollaboratorN/AJun 1, 2020
- NCT04193189CollaboratorPhase 3Jan 21, 2020
- NCT04177355CollaboratorPhase 1Dec 18, 2019
- NCT04050085CollaboratorPhase 1Aug 2, 2019
- NCT03934736Lead sponsorPhase 1Apr 29, 2019
- NCT03934736Study directorPhase 1Apr 29, 2019
- NCT03326752Lead sponsorPhase 1Sep 20, 2017
- NCT02521870Lead sponsorPhase 1/Phase 2Sep 1, 2015
Details
- Founded
- Berkeley, CA, US Jul 1, 1996
- Last known activity
- Sep 11, 2025
Notes
Acquired Symphony Dynamo, Inc 10 Nov 2009 Acquires Rhein Biotech 24 Apr 2018